Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

As of Wednesday, February 18, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 8.15%, which has investors questioning if this is right time to buy.

The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...